<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37315259</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1997-7298</ISSN><JournalIssue CitedMedium="Print"><Volume>123</Volume><Issue>5</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</Title><ISOAbbreviation>Zh Nevrol Psikhiatr Im S S Korsakova</ISOAbbreviation></Journal><ArticleTitle>[The influence of uric acid on the course of amyotrophic lateral sclerosis].</ArticleTitle><Pagination><StartPage>177</StartPage><EndPage>180</EndPage><MedlinePgn>177-180</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.17116/jnevro2023123051177</ELocationID><Abstract><AbstractText>Uric acid has antioxidant and neuroprotective properties. A number of studies show that high levels of uric acid may have a positive influence on the course of amyotrophic lateral sclerosis (ALS), especially in males. The frequency of ALS is lower in patients with gout than in the general population. We present a case of a patient with gout and slowly progressive ALS. More research is needed on the potential role of uric acid in ALS and other neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kutlubaev</LastName><ForeName>M A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-1001-2024</Identifier><AffiliationInfo><Affiliation>Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areprintseva</LastName><ForeName>D K</ForeName><Initials>DK</Initials><Identifier Source="ORCID">0000-0001-5255-2657</Identifier><AffiliationInfo><Affiliation>Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pervushina</LastName><ForeName>E V</ForeName><Initials>EV</Initials><Identifier Source="ORCID">0000-0002-9352-5783</Identifier><AffiliationInfo><Affiliation>Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Vliyanie mochevoi kisloty na techenie bokovogo amiotroficheskogo skleroza.</VernacularTitle></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Zh Nevrol Psikhiatr Im S S Korsakova</MedlineTA><NlmUniqueID>9712194</NlmUniqueID><ISSNLinking>1997-7298</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>268B43MJ25</RegistryNumber><NameOfSubstance UI="D014527">Uric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014527" MajorTopicYN="N">Uric Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006073" MajorTopicYN="Y">Gout</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066829" MajorTopicYN="N">Neuroprotection</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="rus"><AbstractText>&#x41c;&#x43e;&#x447;&#x435;&#x432;&#x430;&#x44f; &#x43a;&#x438;&#x441;&#x43b;&#x43e;&#x442;&#x430; &#x43e;&#x431;&#x43b;&#x430;&#x434;&#x430;&#x435;&#x442; &#x430;&#x43d;&#x442;&#x438;&#x43e;&#x43a;&#x441;&#x438;&#x434;&#x430;&#x43d;&#x442;&#x43d;&#x44b;&#x43c;&#x438; &#x438; &#x43d;&#x435;&#x439;&#x440;&#x43e;&#x43f;&#x440;&#x43e;&#x442;&#x435;&#x43a;&#x442;&#x438;&#x432;&#x43d;&#x44b;&#x43c;&#x438; &#x441;&#x432;&#x43e;&#x439;&#x441;&#x442;&#x432;&#x430;&#x43c;&#x438;. &#x412; &#x440;&#x44f;&#x434;&#x435; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x439; &#x431;&#x44b;&#x43b;&#x43e; &#x43f;&#x43e;&#x43a;&#x430;&#x437;&#x430;&#x43d;&#x43e;, &#x447;&#x442;&#x43e; &#x432;&#x44b;&#x441;&#x43e;&#x43a;&#x438;&#x439; &#x443;&#x440;&#x43e;&#x432;&#x435;&#x43d;&#x44c; &#x43c;&#x43e;&#x447;&#x435;&#x432;&#x43e;&#x439; &#x43a;&#x438;&#x441;&#x43b;&#x43e;&#x442;&#x44b; &#x43c;&#x43e;&#x436;&#x435;&#x442; &#x438;&#x43c;&#x435;&#x442;&#x44c; &#x43f;&#x43e;&#x43b;&#x43e;&#x436;&#x438;&#x442;&#x435;&#x43b;&#x44c;&#x43d;&#x43e;&#x435; &#x432;&#x43b;&#x438;&#x44f;&#x43d;&#x438;&#x435; &#x43d;&#x430; &#x442;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x435; &#x431;&#x43e;&#x43a;&#x43e;&#x432;&#x43e;&#x433;&#x43e; &#x430;&#x43c;&#x438;&#x43e;&#x442;&#x440;&#x43e;&#x444;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x43e;&#x433;&#x43e; &#x441;&#x43a;&#x43b;&#x435;&#x440;&#x43e;&#x437;&#x430; (&#x411;&#x410;&#x421;), &#x43e;&#x441;&#x43e;&#x431;&#x435;&#x43d;&#x43d;&#x43e; &#x443; &#x43c;&#x443;&#x436;&#x447;&#x438;&#x43d;. &#x427;&#x430;&#x441;&#x442;&#x43e;&#x442;&#x430; &#x411;&#x410;&#x421; &#x43d;&#x438;&#x436;&#x435; &#x443; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; &#x441; &#x43f;&#x43e;&#x434;&#x430;&#x433;&#x440;&#x43e;&#x439;, &#x447;&#x435;&#x43c; &#x432; &#x43f;&#x43e;&#x43f;&#x443;&#x43b;&#x44f;&#x446;&#x438;&#x438; &#x432; &#x446;&#x435;&#x43b;&#x43e;&#x43c;. &#x41f;&#x440;&#x435;&#x434;&#x441;&#x442;&#x430;&#x432;&#x43b;&#x435;&#x43d;&#x43e; &#x43a;&#x43b;&#x438;&#x43d;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x43e;&#x435; &#x43d;&#x430;&#x431;&#x43b;&#x44e;&#x434;&#x435;&#x43d;&#x438;&#x435; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x430; &#x441; &#x411;&#x410;&#x421; &#x438; &#x43f;&#x43e;&#x434;&#x430;&#x433;&#x440;&#x43e;&#x439; &#x441; &#x43e;&#x442;&#x43d;&#x43e;&#x441;&#x438;&#x442;&#x435;&#x43b;&#x44c;&#x43d;&#x43e; &#x43c;&#x435;&#x434;&#x43b;&#x435;&#x43d;&#x43d;&#x44b;&#x43c; &#x43f;&#x440;&#x43e;&#x433;&#x440;&#x435;&#x441;&#x441;&#x438;&#x440;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x435;&#x43c; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x43d;&#x438;&#x44f;. &#x41d;&#x435;&#x43e;&#x431;&#x445;&#x43e;&#x434;&#x438;&#x43c;&#x44b; &#x434;&#x430;&#x43b;&#x44c;&#x43d;&#x435;&#x439;&#x448;&#x438;&#x435; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x44f; &#x432;&#x43e;&#x437;&#x43c;&#x43e;&#x436;&#x43d;&#x43e;&#x439; &#x440;&#x43e;&#x43b;&#x438; &#x43c;&#x43e;&#x447;&#x435;&#x432;&#x43e;&#x439; &#x43a;&#x438;&#x441;&#x43b;&#x43e;&#x442;&#x44b; &#x43f;&#x440;&#x438; &#x411;&#x410;&#x421; &#x438; &#x434;&#x440;&#x443;&#x433;&#x438;&#x445; &#x43d;&#x435;&#x439;&#x440;&#x43e;&#x434;&#x435;&#x433;&#x435;&#x43d;&#x435;&#x440;&#x430;&#x442;&#x438;&#x432;&#x43d;&#x44b;&#x445; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x43d;&#x438;&#x44f;&#x445;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">antioxidant</Keyword><Keyword MajorTopicYN="N">gout</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">uric acid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>19</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>15</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37315259</ArticleId><ArticleId IdType="doi">10.17116/jnevro2023123051177</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>